超低分割放疗联合HDR近距离治疗中危前列腺癌
本研究评估超低分割放疗(UHF,25 Gy/5次)联合HDR近距离治疗推量(HDR-BB,15 Gy)治疗中危前列腺癌的安全性和疗效,并与两个历史对照组(36 Gy/12次和37.5 Gy/15次联合相同HDR-BB)比较。结果显示UHF组4年生化治愈率81.8%,与对照组无统计学差异,且无3级毒性,提示UHF方案安全并减少治疗时间和患者负担。
要点
- UHF方案为25 Gy/5次联合15 Gy HDR-BB,4年生化治愈率81.8%。
- UHF组无3级毒性,对照组分别为0.7%和5.1%。
- 三组间无生化复发无生存和总生存差异,晚期泌尿生殖和胃肠道毒性无差异。
核心结论
- UHF联合HDR-BB治疗中危前列腺癌安全,可减少治疗时间和患者负担。
研究设计与样本
- 研究纳入199例中危前列腺癌患者接受UHF(25 Gy/5次+15 Gy HDR-BB),与两个历史对照组(36 Gy/12次152例和37.5 Gy/15次311例,均联合相同HDR-BB)比较。
主要发现
- 中位随访时间UHF组36个月,36 Gy组90个月,37.5 Gy组102个月。
- 4年生化治愈率(PSA<0.2 ng/ml)UHF组81.8%,36 Gy组78.4%,37.5 Gy组66.7%(p=0.11)。
- 三组间生化复发无生存和总生存无统计学差异。
- UHF组无3级毒性,36 Gy组0.7%,37.5 Gy组5.1%。
- 晚期泌尿生殖和胃肠道毒性组间无差异。
关键数值与推荐
- 生化治愈率定义为4年时PSA<0.2 ng/ml。
- UHF方案:25 Gy分5次联合15 Gy HDR-BB。
- 对照方案:36 Gy分12次或37.5 Gy分15次联合相同HDR-BB。
临床怎么用
- UHF联合HDR-BB可作为中危前列腺癌的治疗选择,缩短治疗时间并降低患者负担。
局限性
- UHF组随访时间较短(中位36个月),需要更长时间随访确认结果。
- 研究为与历史对照组比较,非随机对照设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate safety and efficacy of ultra hypofractionated radiotherapy (UHF) combined with high dose rate brachytherapy boost (HDR-BB) in comparison to a moderately hypo-fractionated (MHF) regimen, in patients treated for intermediate risk prostate cancer. MATERIALS/METHODS: 199 patients with intermediate risk prostate cancer were recruited in the experimental UHF treatment cohort of 25 Gy in 5 fractions plus a 15 Gy HDR-BB. They were compared to two historical control groups, treated with either 36 Gy in 12 fractions (152 patients) or 37.5 Gy in 15 fractions (311 patients) with an identical HDR-BB. The study reported the biochemical cure rate (BCR) defined as PSA < 0.2 ng/ml at 4 years, as well as biochemical relapse-free survival (BRFS) and overall survival (OS). Additionally, genitourinary (GU), gastrointestinal (GI), and sexual toxicities were evaluated. RESULTS: At the time of analysis, median follow up was respectively 36, 90 and 102 months for the UHF, 36 Gy and 37.5 Gy group. The BCR was 81.8 %, 78.4 % and 66.7 % in the UHF and both MHF groups (p = 0.11). There was no statistical difference in BRFS and OS between the three groups. There was no grade 3 toxicity in UHF group compared to 0.7 % in 36 Gy and 5.1 % in 37.5 Gy groups. No difference was found in late GU and GI toxicities between groups. CONCLUSION: Our study confirms UHF with HDR-BB is safe for intermediate-risk prostate cancer, reducing treatment time and patient burden. Longer follow-up is needed to confirm results.
引用
- Sidibé I, Beaudry MM, Carignan D, et al. Ultra-hypofractionated radiotherapy combined with HDR brachytherapy: An optimized treatment. Radiother Oncol. 2025. PMID: 41067642. doi:10.1016/j.radonc.2025.111199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。